Difference between revisions of "Team:CPU CHINA"

 
(45 intermediate revisions by 2 users not shown)
Line 25: Line 25:
 
     <div class="body-container">
 
     <div class="body-container">
  
             <center class="pagee pagee1">
+
             <center class="pagee pagee0" id="dyk">
 +
            <p><br>&nbsp;<br></p>
 
             <p><br>&nbsp;<br></p>
 
             <p><br>&nbsp;<br></p>
 
             <p><br>&nbsp;<br></p>
 
             <p><br>&nbsp;<br></p>
 +
         
 
             <img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300">
 
             <img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300">
 
             </center>
 
             </center>
  
             <center class="pagee pagee2">
+
             <center class="pagee pagee1">
 
             <p><br>&nbsp;<br></p>
 
             <p><br>&nbsp;<br></p>
 +
   
 +
             
 
            <h5 style="padding: 0px; margin: 5px;">Our HEAD-Treg</h5>
 
            <h5 style="padding: 0px; margin: 5px;">Our HEAD-Treg</h5>
            <video src="https://static.igem.org/mediawiki/2017/1/14/T--CPU_CHINA--mainpagevideo.mp4" controls="controls" class="video" width = "60%"></video>
+
            <video src="https://static.igem.org/mediawiki/2017/5/5a/T--CPU_CHINA--V123.mp4" controls="controls" class="video" width = "55%"></video>
 
             </center>
 
             </center>
  
             <center class="pagee pagee3">
+
             <center class="pagee pagee2">
            <p><br>&nbsp;<br></p>
+
                <p><br>&nbsp;<br></p>
 
             <p><br>&nbsp;<br></p>
 
             <p><br>&nbsp;<br></p>
 
             <h5 style="padding: 0px; margin: 0px;">Description</h5>
 
             <h5 style="padding: 0px; margin: 0px;">Description</h5>
Line 48: Line 52:
 
                     inflammatory environment, which enables them to play their role of immunosuppression in lesions more
 
                     inflammatory environment, which enables them to play their role of immunosuppression in lesions more
 
                     efficiently and more stably. <br>These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4>
 
                     efficiently and more stably. <br>These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4>
 
+
                          <p><br>&nbsp;<br></p>
 +
                       
 
<center class="footer-left">
 
<center class="footer-left">
  <p class="footer-links">
+
  <p class="footer-links" style="text-align:center;">
 
<a target="_blank" href="https://www.cpu.edu.cn">
 
<a target="_blank" href="https://www.cpu.edu.cn">
 
        <img class="sponsors" src="https://static.igem.org/mediawiki/2017/5/52/T--CPU_CHINA--cpu_logo_new_1.png"></a>
 
        <img class="sponsors" src="https://static.igem.org/mediawiki/2017/5/52/T--CPU_CHINA--cpu_logo_new_1.png"></a>
Line 63: Line 68:
 
        <a target="_blank" href="https://www.genscript.com/">
 
        <a target="_blank" href="https://www.genscript.com/">
 
        <img class="sponsors" src="https://static.igem.org/mediawiki/2017/3/38/T--CPU_CHINA--cpu_logogenscript.png"></a>
 
        <img class="sponsors" src="https://static.igem.org/mediawiki/2017/3/38/T--CPU_CHINA--cpu_logogenscript.png"></a>
 +
        <a target="_blank" href="javascript:();">
 +
        <img class="sponsors" src="https://static.igem.org/mediawiki/2017/d/da/Cyva.jpg"></a>
 +
                                <a target="_blank" href="javascript:();">
 +
                                <img class="sponsors" src="https://static.igem.org/mediawiki/2017/1/17/T--CPU_CHINA--cpu_sponsors_11_contect_2.png"></a>
 
  </p>
 
  </p>
 
</center>
 
</center>
Line 137: Line 146:
 
  .sponsors {
 
  .sponsors {
 
             margin: 2.5px;
 
             margin: 2.5px;
             width: 175px;
+
             width: 150px;
 
         }
 
         }
  
Line 279: Line 288:
 
}
 
}
 
</style>
 
</style>
 +
 +
 +
<script type="text/javascript">
 +
!function(e){var t={sectionContainer:"section",easing:"ease",animationTime:1e3,pagination:true,updateURL:false,keyboard:true,beforeMove:null,afterMove:null,loop:true,responsiveFallback:false,direction:"vertical"};e.fn.swipeEvents=function(){return this.each(function(){function i(e){var i=e.originalEvent.touches;if(i&&i.length){t=i[0].pageX;n=i[0].pageY;r.bind("touchmove",s)}}function s(e){var i=e.originalEvent.touches;if(i&&i.length){var o=t-i[0].pageX;var u=n-i[0].pageY;if(o>=50){r.trigger("swipeLeft")}if(o<=-50){r.trigger("swipeRight")}if(u>=50){r.trigger("swipeUp")}if(u<=-50){r.trigger("swipeDown")}if(Math.abs(o)>=50||Math.abs(u)>=50){r.unbind("touchmove",s)}}}var t,n,r=e(this);r.bind("touchstart",i)})};e.fn.onepage_scroll=function(n){function o(){var t=false;var n=typeof r.responsiveFallback;if(n=="number"){t=e(window).width()<r.responsiveFallback}if(n=="boolean"){t=r.responsiveFallback}if(n=="function"){valFunction=r.responsiveFallback();t=valFunction;typeOFv=typeof t;if(typeOFv=="number"){t=e(window).width()<valFunction}}if(t){e("body").addClass("disabled-onepage-scroll");e(document).unbind("mousewheel DOMMouseScroll MozMousePixelScroll");i.swipeEvents().unbind("swipeDown swipeUp")}else{if(e("body").hasClass("disabled-onepage-scroll")){e("body").removeClass("disabled-onepage-scroll");e("html, body, .wrapper").animate({scrollTop:0},"fast")}i.swipeEvents().bind("swipeDown",function(t){if(!e("body").hasClass("disabled-onepage-scroll"))t.preventDefault();i.moveUp()}).bind("swipeUp",function(t){if(!e("body").hasClass("disabled-onepage-scroll"))t.preventDefault();i.moveDown()});e(document).bind("mousewheel DOMMouseScroll MozMousePixelScroll",function(e){e.preventDefault();var t=e.originalEvent.wheelDelta||-e.originalEvent.detail;u(e,t)})}}function u(e,t){deltaOfInterest=t;var n=(new Date).getTime();if(n-lastAnimation<quietPeriod+r.animationTime){e.preventDefault();return}if(deltaOfInterest<0){i.moveDown()}else{i.moveUp()}lastAnimation=n}var r=e.extend({},t,n),i=e(this),s=e(r.sectionContainer);total=s.length,status="off",topPos=0,leftPos=0,lastAnimation=0,quietPeriod=500,paginationList="";e.fn.transformPage=function(t,n,r){if(typeof t.beforeMove=="function")t.beforeMove(r);e(this).css({"-webkit-transform":t.direction=="horizontal"?"translate3d("+n+"%, 0, 0)":"translate3d(0, "+n+"%, 0)","-webkit-transition":"all "+t.animationTime+"ms "+t.easing,"-moz-transform":t.direction=="horizontal"?"translate3d("+n+"%, 0, 0)":"translate3d(0, "+n+"%, 0)","-moz-transition":"all "+t.animationTime+"ms "+t.easing,"-ms-transform":t.direction=="horizontal"?"translate3d("+n+"%, 0, 0)":"translate3d(0, "+n+"%, 0)","-ms-transition":"all "+t.animationTime+"ms "+t.easing,transform:t.direction=="horizontal"?"translate3d("+n+"%, 0, 0)":"translate3d(0, "+n+"%, 0)",transition:"all "+t.animationTime+"ms "+t.easing});e(this).one("webkitTransitionEnd otransitionend oTransitionEnd msTransitionEnd transitionend",function(e){if(typeof t.afterMove=="function")t.afterMove(r)})};e.fn.moveDown=function(){var t=e(this);index=e(r.sectionContainer+".active").data("index");current=e(r.sectionContainer+"[data-index='"+index+"']");next=e(r.sectionContainer+"[data-index='"+(index+1)+"']");if(next.length<1){if(r.loop==true){pos=0;next=e(r.sectionContainer+"[data-index='1']")}else{return}}else{pos=index*100*-1}if(typeof r.beforeMove=="function")r.beforeMove(next.data("index"));current.removeClass("active");next.addClass("active");if(r.pagination==true){e(".onepage-pagination li a"+"[data-index='"+index+"']").removeClass("active");e(".onepage-pagination li a"+"[data-index='"+next.data("index")+"']").addClass("active")}e("body")[0].className=e("body")[0].className.replace(/\bviewing-page-\d.*?\b/g,"");e("body").addClass("viewing-page-"+next.data("index"));if(history.replaceState&&r.updateURL==true){var n=window.location.href.substr(0,window.location.href.indexOf("#"))+"#"+(index+1);history.pushState({},document.title,n)}t.transformPage(r,pos,next.data("index"))};e.fn.moveUp=function(){var t=e(this);index=e(r.sectionContainer+".active").data("index");current=e(r.sectionContainer+"[data-index='"+index+"']");next=e(r.sectionContainer+"[data-index='"+(index-1)+"']");if(next.length<1){if(r.loop==true){pos=(total-1)*100*-1;next=e(r.sectionContainer+"[data-index='"+total+"']")}else{return}}else{pos=(next.data("index")-1)*100*-1}if(typeof r.beforeMove=="function")r.beforeMove(next.data("index"));current.removeClass("active");next.addClass("active");if(r.pagination==true){e(".onepage-pagination li a"+"[data-index='"+index+"']").removeClass("active");e(".onepage-pagination li a"+"[data-index='"+next.data("index")+"']").addClass("active")}e("body")[0].className=e("body")[0].className.replace(/\bviewing-page-\d.*?\b/g,"");e("body").addClass("viewing-page-"+next.data("index"));if(history.replaceState&&r.updateURL==true){var n=window.location.href.substr(0,window.location.href.indexOf("#"))+"#"+(index-1);history.pushState({},document.title,n)}t.transformPage(r,pos,next.data("index"))};e.fn.moveTo=function(t){current=e(r.sectionContainer+".active");next=e(r.sectionContainer+"[data-index='"+t+"']");if(next.length>0){if(typeof r.beforeMove=="function")r.beforeMove(next.data("index"));current.removeClass("active");next.addClass("active");e(".onepage-pagination li a"+".active").removeClass("active");e(".onepage-pagination li a"+"[data-index='"+t+"']").addClass("active");e("body")[0].className=e("body")[0].className.replace(/\bviewing-page-\d.*?\b/g,"");e("body").addClass("viewing-page-"+next.data("index"));pos=(t-1)*100*-1;if(history.replaceState&&r.updateURL==true){var n=window.location.href.substr(0,window.location.href.indexOf("#"))+"#"+(t-1);history.pushState({},document.title,n)}i.transformPage(r,pos,t)}};i.addClass("onepage-wrapper").css("position","relative");e.each(s,function(t){e(this).css({position:"absolute",top:topPos+"%"}).addClass("section").attr("data-index",t+1);e(this).css({position:"absolute",left:r.direction=="horizontal"?leftPos+"%":0,top:r.direction=="vertical"||r.direction!="horizontal"?topPos+"%":0});if(r.direction=="horizontal")leftPos=leftPos+100;else topPos=topPos+100;if(r.pagination==true){paginationList+="<li><a data-index='"+(t+1)+"' href='#"+(t+1)+"'></a></li>"}});i.swipeEvents().bind("swipeDown",function(t){if(!e("body").hasClass("disabled-onepage-scroll"))t.preventDefault();i.moveUp()}).bind("swipeUp",function(t){if(!e("body").hasClass("disabled-onepage-scroll"))t.preventDefault();i.moveDown()});if(r.pagination==true){if(e("ul.onepage-pagination").length<1)e("<ul class='onepage-pagination'></ul>").prependTo("body");if(r.direction=="horizontal"){posLeft=i.find(".onepage-pagination").width()/2*-1;i.find(".onepage-pagination").css("margin-left",posLeft)}else{posTop=i.find(".onepage-pagination").height()/2*-1;i.find(".onepage-pagination").css("margin-top",posTop)}e("ul.onepage-pagination").html(paginationList)}if(window.location.hash!=""&&window.location.hash!="#1"){init_index=window.location.hash.replace("#","");if(parseInt(init_index)<=total&&parseInt(init_index)>0){e(r.sectionContainer+"[data-index='"+init_index+"']").addClass("active");e("body").addClass("viewing-page-"+init_index);if(r.pagination==true)e(".onepage-pagination li a"+"[data-index='"+init_index+"']").addClass("active");next=e(r.sectionContainer+"[data-index='"+init_index+"']");if(next){next.addClass("active");if(r.pagination==true)e(".onepage-pagination li a"+"[data-index='"+init_index+"']").addClass("active");e("body")[0].className=e("body")[0].className.replace(/\bviewing-page-\d.*?\b/g,"");e("body").addClass("viewing-page-"+next.data("index"));if(history.replaceState&&r.updateURL==true){var a=window.location.href.substr(0,window.location.href.indexOf("#"))+"#"+init_index;history.pushState({},document.title,a)}}pos=(init_index-1)*100*-1;i.transformPage(r,pos,init_index)}else{e(r.sectionContainer+"[data-index='1']").addClass("active");e("body").addClass("viewing-page-1");if(r.pagination==true)e(".onepage-pagination li a"+"[data-index='1']").addClass("active")}}else{e(r.sectionContainer+"[data-index='1']").addClass("active");e("body").addClass("viewing-page-1");if(r.pagination==true)e(".onepage-pagination li a"+"[data-index='1']").addClass("active")}if(r.pagination==true){e(".onepage-pagination li a").click(function(){var t=e(this).data("index");i.moveTo(t)})}e(document).bind("mousewheel DOMMouseScroll MozMousePixelScroll",function(t){t.preventDefault();var n=t.originalEvent.wheelDelta||-t.originalEvent.detail;if(!e("body").hasClass("disabled-onepage-scroll"))u(t,n)});if(r.responsiveFallback!=false){e(window).resize(function(){o()});o()}if(r.keyboard==true){e(document).keydown(function(t){var n=t.target.tagName.toLowerCase();if(!e("body").hasClass("disabled-onepage-scroll")){switch(t.which){case 38:if(n!="input"&&n!="textarea")i.moveUp();break;case 40:if(n!="input"&&n!="textarea")i.moveDown();break;case 33:if(n!="input"&&n!="textarea")i.moveUp();break;case 34:if(n!="input"&&n!="textarea")i.moveDown();break;case 36:i.moveTo(1);break;case 35:i.moveTo(total);break;default:return}}})}return false}}(window.jQuery)
 +
</script>
 +
 +
<script>
 +
$(document).ready(function(){
 +
document.getElementById('dyk').style.position="relative";
 +
});
 +
document.getElementById('dyk').style.position="relative";
 +
</script>
  
 
</html>
 
</html>

Latest revision as of 03:20, 2 November 2017


 


 


 


 

Our HEAD-Treg


 


 

Description

Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease.
It is of great essence to develop a novel cell-targeted therapy for RA because there is no radical cure for RA for the time being.
To solve the problems existing in the current treatment of RA, we design and build a brand new immunotherapy.
FOXP3+ regulatory T cells(Tregs), which can suppress and regulate immune reactions, are modified
utilizing a lentiviral vector system to express a chimeric antigen receptor(CAR) targeting inflammatory cells associated with RA.
Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the inflammatory environment, which enables them to play their role of immunosuppression in lesions more efficiently and more stably.
These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect.